• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Hypometabolism in Healthy Brains May Indicate Pre-Alzheimer’s


PET finds hypometabolism in healthy brains that may indicate pre-Alzheimer’s disease.

PET images detected an association between hypometabolism and amyloid in brains of people with pre-Alzheimer’s who don’t show any signs of cognitive decline, according to presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2013 annual meeting.

The amyloid plaque build-up in the brain in Alzheimer’s is known, but now there appears to be a connection between the amyloid burden and hypometabolism of neurons in parts of the brain that have been associated with Alzheimer’s disease.

“Previous studies indicate that hypometabolism of this same pattern is present in people who have abnormalities of the gene apolipoprotein E, or APOE,” Val J. Lowe, MD, professor of radiology at Mayo Clinic Cancer Center, said in a release. “Hypometabolism does appear to be an early harbinger of the disease before dementia sets in.”.

Researchers from the Mayo Clinic Study of Aging studied PET images of 617 cognitively normal subjects. Each subject first underwent imaging with the amyloid-binding radionuclide imaging agent C-11 Pittsburgh compound B (PiB), followed an hour later with a second exam which used F018 fluorodeoxyglucose (FDG).

The researchers found that there was significant hypometabolism in brain regions classically associated with Alzheimer’s disease, including the angular gyrus and posterior cingulate.

The researchers will continue to follow the subjects to see if they progress to Alzheimer’s disease, and to study the ones do not develop the disease but do have amyloid in their brain.

Related Videos
Emerging Innovations in Molecular Imaging
Ultra-High Resolution Brain PET: A ‘Quantum Leap’ for Neuroradiology
Emerging PET Radiotracer May Improve Detection of Coronary Artery Disease in Obese Patients
Can SPECT/CT Guidance Facilitate Personalized Dosing for Patients with Prostate Cancer?
New Research Shows Viability of PET Imaging Agent for Clear Cell Renal Cell Carcinoma
A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging
Related Content
© 2024 MJH Life Sciences

All rights reserved.